Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder

C. N. Sternberg, V. Pansadoro, F. Calabrò, L. Marini, A. Van Rijn, P. De Carli, D. Giannarelli, A. Platania, A. Rossetti

Research output: Contribution to journalArticle

Abstract

Background: The possibility of bladder preservation as well as the utility of neo-adjuvant chemotherapy for invasive bladder cancer are controversial issues. The purpose of this study was the evaluation of neo- adjuvant M-VAC chemotherapy and bladder preservation in patients with locally advanced transitional cell carcinoma of the bladder. Patients and methods: Eighty-seven consecutive evaluable patients with T2-T(4a)N(x)M0 TCC of the bladder were treated with three cycles of neo-adjuvant M-VAC chemotherapy. After three cycles of M-VAC, 42 patients had TURB alone, 13 patients underwent partial cystectomy, and 32 patients were to undergo radical cystectomy. Results: Forty (51%) patients were T0 at the TURB following M- VAC. Thirty (71%) patients who had chemotherapy and TURB alone are alive; at a median follow-up of 54+ months (8+-109+). Twenty-four (57%) have maintained an intact bladder. Of 13 responding patients with monofocal lesions who underwent partial cystectomy, 8 patients (62%) are alive with a functioning bladder, at a median follow-up of 80+ months (16-107+ months). At a follow-up of 32 months (7-121+ months), 20 (63%) patients in the radical cystectomy group are alive. In patients who had downstaging to T0 or superficial disease, median follow-up is 55 months (10-121+ months) and five-year survival is 71%. Patients who failed to respond (T2 or greater after chemotherapy), at a median follow-up of 24 months (7-103+ months), had five- year survival of only 29%. Conclusions: Bladder sparing in selected patients on the basis of response to neo-adjuvant chemotherapy is a feasible approach which must be confirmed in prospective randomized trials.

Original languageEnglish
Pages (from-to)1301-1305
Number of pages5
JournalAnnals of Oncology
Volume10
Issue number11
DOIs
Publication statusPublished - 1999

Fingerprint

Transitional Cell Carcinoma
Adjuvant Chemotherapy
Urinary Bladder
Cystectomy
Drug Therapy
Survival
Urinary Bladder Neoplasms

Keywords

  • Bladder preservation
  • Locally advanced bladder cancer
  • Neo-adjuvant chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder. / Sternberg, C. N.; Pansadoro, V.; Calabrò, F.; Marini, L.; Van Rijn, A.; De Carli, P.; Giannarelli, D.; Platania, A.; Rossetti, A.

In: Annals of Oncology, Vol. 10, No. 11, 1999, p. 1301-1305.

Research output: Contribution to journalArticle

Sternberg, CN, Pansadoro, V, Calabrò, F, Marini, L, Van Rijn, A, De Carli, P, Giannarelli, D, Platania, A & Rossetti, A 1999, 'Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder', Annals of Oncology, vol. 10, no. 11, pp. 1301-1305. https://doi.org/10.1023/A:1008350518083
Sternberg, C. N. ; Pansadoro, V. ; Calabrò, F. ; Marini, L. ; Van Rijn, A. ; De Carli, P. ; Giannarelli, D. ; Platania, A. ; Rossetti, A. / Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder. In: Annals of Oncology. 1999 ; Vol. 10, No. 11. pp. 1301-1305.
@article{de011b7b84484c28a5de75d53beb6a76,
title = "Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder",
abstract = "Background: The possibility of bladder preservation as well as the utility of neo-adjuvant chemotherapy for invasive bladder cancer are controversial issues. The purpose of this study was the evaluation of neo- adjuvant M-VAC chemotherapy and bladder preservation in patients with locally advanced transitional cell carcinoma of the bladder. Patients and methods: Eighty-seven consecutive evaluable patients with T2-T(4a)N(x)M0 TCC of the bladder were treated with three cycles of neo-adjuvant M-VAC chemotherapy. After three cycles of M-VAC, 42 patients had TURB alone, 13 patients underwent partial cystectomy, and 32 patients were to undergo radical cystectomy. Results: Forty (51{\%}) patients were T0 at the TURB following M- VAC. Thirty (71{\%}) patients who had chemotherapy and TURB alone are alive; at a median follow-up of 54+ months (8+-109+). Twenty-four (57{\%}) have maintained an intact bladder. Of 13 responding patients with monofocal lesions who underwent partial cystectomy, 8 patients (62{\%}) are alive with a functioning bladder, at a median follow-up of 80+ months (16-107+ months). At a follow-up of 32 months (7-121+ months), 20 (63{\%}) patients in the radical cystectomy group are alive. In patients who had downstaging to T0 or superficial disease, median follow-up is 55 months (10-121+ months) and five-year survival is 71{\%}. Patients who failed to respond (T2 or greater after chemotherapy), at a median follow-up of 24 months (7-103+ months), had five- year survival of only 29{\%}. Conclusions: Bladder sparing in selected patients on the basis of response to neo-adjuvant chemotherapy is a feasible approach which must be confirmed in prospective randomized trials.",
keywords = "Bladder preservation, Locally advanced bladder cancer, Neo-adjuvant chemotherapy",
author = "Sternberg, {C. N.} and V. Pansadoro and F. Calabr{\`o} and L. Marini and {Van Rijn}, A. and {De Carli}, P. and D. Giannarelli and A. Platania and A. Rossetti",
year = "1999",
doi = "10.1023/A:1008350518083",
language = "English",
volume = "10",
pages = "1301--1305",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "11",

}

TY - JOUR

T1 - Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder

AU - Sternberg, C. N.

AU - Pansadoro, V.

AU - Calabrò, F.

AU - Marini, L.

AU - Van Rijn, A.

AU - De Carli, P.

AU - Giannarelli, D.

AU - Platania, A.

AU - Rossetti, A.

PY - 1999

Y1 - 1999

N2 - Background: The possibility of bladder preservation as well as the utility of neo-adjuvant chemotherapy for invasive bladder cancer are controversial issues. The purpose of this study was the evaluation of neo- adjuvant M-VAC chemotherapy and bladder preservation in patients with locally advanced transitional cell carcinoma of the bladder. Patients and methods: Eighty-seven consecutive evaluable patients with T2-T(4a)N(x)M0 TCC of the bladder were treated with three cycles of neo-adjuvant M-VAC chemotherapy. After three cycles of M-VAC, 42 patients had TURB alone, 13 patients underwent partial cystectomy, and 32 patients were to undergo radical cystectomy. Results: Forty (51%) patients were T0 at the TURB following M- VAC. Thirty (71%) patients who had chemotherapy and TURB alone are alive; at a median follow-up of 54+ months (8+-109+). Twenty-four (57%) have maintained an intact bladder. Of 13 responding patients with monofocal lesions who underwent partial cystectomy, 8 patients (62%) are alive with a functioning bladder, at a median follow-up of 80+ months (16-107+ months). At a follow-up of 32 months (7-121+ months), 20 (63%) patients in the radical cystectomy group are alive. In patients who had downstaging to T0 or superficial disease, median follow-up is 55 months (10-121+ months) and five-year survival is 71%. Patients who failed to respond (T2 or greater after chemotherapy), at a median follow-up of 24 months (7-103+ months), had five- year survival of only 29%. Conclusions: Bladder sparing in selected patients on the basis of response to neo-adjuvant chemotherapy is a feasible approach which must be confirmed in prospective randomized trials.

AB - Background: The possibility of bladder preservation as well as the utility of neo-adjuvant chemotherapy for invasive bladder cancer are controversial issues. The purpose of this study was the evaluation of neo- adjuvant M-VAC chemotherapy and bladder preservation in patients with locally advanced transitional cell carcinoma of the bladder. Patients and methods: Eighty-seven consecutive evaluable patients with T2-T(4a)N(x)M0 TCC of the bladder were treated with three cycles of neo-adjuvant M-VAC chemotherapy. After three cycles of M-VAC, 42 patients had TURB alone, 13 patients underwent partial cystectomy, and 32 patients were to undergo radical cystectomy. Results: Forty (51%) patients were T0 at the TURB following M- VAC. Thirty (71%) patients who had chemotherapy and TURB alone are alive; at a median follow-up of 54+ months (8+-109+). Twenty-four (57%) have maintained an intact bladder. Of 13 responding patients with monofocal lesions who underwent partial cystectomy, 8 patients (62%) are alive with a functioning bladder, at a median follow-up of 80+ months (16-107+ months). At a follow-up of 32 months (7-121+ months), 20 (63%) patients in the radical cystectomy group are alive. In patients who had downstaging to T0 or superficial disease, median follow-up is 55 months (10-121+ months) and five-year survival is 71%. Patients who failed to respond (T2 or greater after chemotherapy), at a median follow-up of 24 months (7-103+ months), had five- year survival of only 29%. Conclusions: Bladder sparing in selected patients on the basis of response to neo-adjuvant chemotherapy is a feasible approach which must be confirmed in prospective randomized trials.

KW - Bladder preservation

KW - Locally advanced bladder cancer

KW - Neo-adjuvant chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0032764063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032764063&partnerID=8YFLogxK

U2 - 10.1023/A:1008350518083

DO - 10.1023/A:1008350518083

M3 - Article

C2 - 10631456

AN - SCOPUS:0032764063

VL - 10

SP - 1301

EP - 1305

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 11

ER -